ANGLE plc

Liquid biopsy could transform cancer care, but costs continue to be a major obstacle to liquid biopsy adoption and use, particularly in developing geographies. From discovery to treatment and to recur

Liquid biopsy could transform cancer care, but costs continue to be a major obstacle to liquid biopsy adoption and use, particularly in developing geographies. From discovery to treatment and to recur

The US Food and Drug Administration has granted de novo authorization to UK-based Angle 's Parsortix device, making it the first device approved by the regulator capable of capturing circulating tumo

Angle ’s core strategy is “all about getting the best sample,” Angle CEO Andrew Newland explained at the 2021 Jefferies Healthcare Conference on 17 November. “Cancer is heterogenous; it’s dynamic,” he